ArticleAsian Pacific journal of cancer prevention : APJCP2025
Prognostic Role of Musashi-2 Immunohistochemical Expression and CD163+ Tumor- Associated Macrophages in Colorectal Cancer Progression.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreoperative assessment of colorectal cancer requires a multimodal approach including clinical, radiographic, biochemical and colonoscopic assessment with histologic review of biopsies that provides valuable information regarding tumor grading and other significant prognostic factors that aid in determination of the appropriate treatment. The association between Musashi-2 expression and clinicopathological features and its prognostic significance in CRC patients is still controversial. Our study is designed to investigate the expression and prognostic significance of MSI2 and CD163+Tumor associated macrophages in colorectal cancer patients.
methodsProspective longitudinal study was designed including 114 CRC cases from Tropical Medicine Department and Oncology Center, Mansoura University Hospitals, during the period from July 2021 to October 2024, all cases were diagnosed by colonoscopy then underwent radical surgery with biopsies which were examined by IHC staining for MSI2 and CD163+TAM using tissue microarray technique trying to find out their correlation with clinicopathological parameters and patients prognosis.
resultsAmong 114 CRC cases, high MSI2 expression was detected in 49 (43%). MSI2 expression was significantly related to grade of differentiation (P = 0.001*), depth of invasion (P = 0.001*), lymph node metastasis (P = 0.001*), TNM stage (P = 0.001*) and hepatic metastasis (P = 0.009*). Multivariate analysis spotted MSI2 expression as a predictor for Overall survival in CRC (P = 0.015*) and disease free survival (P = 0.008*). CD163+TAM showed a significant correlation to grade of differentiation (P = 0.001*), depth of invasion (P = 0.05*), lymph node metastasis (P = 0.001*), TNM stage (P = 0.001*), and hepatic metastasis (P = 0.007*). Multivariate analysis spotted CD163+TAM expression as a predictor for OS in CRC (P = 0.037*) and DFS (P = 0.003*).
conclusionMSI2 and CD163+TAM are independent prognostic factors for the overall survival and disease free survival and can predict poor prognosis in CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.